Flexible vs. Fixed Diuretic Regimen in the Management of Chronic Heart Failure: A Pilot Study
NCT05594823 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2023-03-13
Summary
Heart failure is a major cause of death and hospitalization in Canada. Many of the symptoms experienced by patients with heart failure relate to having fluid accumulate in the lungs causing difficulty breathing, swelling in the legs, and an increase in weight. Thus, one of the cornerstones of managing heart failure includes the use of medications known as diuretics that target the kidneys to reduce fluid accumulation via urination. Deciding on the correct dose of this medication can be quite nuanced as under-dosing can lead to accumulation of fluid, and over-dosing can dehydrate patients and potentially result in lightheadedness/fainting and damage to the kidneys. Currently, options for prescribing diuretics for heart failure include 1) giving patients a regular, fixed dose or 2) having patients monitor their daily weight as a surrogate of their fluid status and then take a dose of diuretic based on a pre-prepared scale. The rationale behind the flexible weight-based diuretic scale is that it can potentially detect early fluid accumulation and thus possibly prevent hospitalization or ED visits, and it also avoids over-dosing and potentially dehydrating patients. Currently, it is not clear whether the flexible diuretic regimen is better than the fixed-dose regimen in preventing ED visits, hospitalizations, kidney damage, or death and as such, this pilot study will directly compare the two commonly used regimens in the management of chronic heart failure patients.
Conditions
- Heart Failure
- Heart Diseases
Interventions
- OTHER
-
Ambulatory heart failure management with Flexible Diuretic Regimen with furosemide
Subjects will be given a regimen that determines a variable daily dose of diuretic (furosemide) based on daily self-measured weights as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
- OTHER
-
Ambulatory heart failure management with fixed dose furosemide
Subjects will be prescribed a fixed daily dose of diuretic (furosemide) as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
Sponsors & Collaborators
-
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
lead OTHER
Principal Investigators
-
Stuart Smith, MD · Western University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-03
- Primary Completion
- 2023-07-31
- Completion
- 2023-07-31
- FDA Drug
- Yes
Countries
- Canada
Study Locations
More Related Trials
-
Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion
NCT03592836 ·Status: COMPLETED ·Phase: PHASE3
-
PHARM Optimal-HF Pilot
NCT05623358 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of Dietary Intervention Under 100 MMOL in Heart Failure
NCT01480401 ·Status: COMPLETED ·Phase: NA
-
1 Year Post Discharge Prognostic Model From the National Heart Failure Audit (NHFA)
NCT02353481 ·Status: UNKNOWN
-
Diastology-Guided Management of Decompensated Heart Failure
NCT06131008 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Patient-centered Care Transitions in Heart Failure: A Pragmatic Cluster Randomized Trial
NCT02112227 ·Status: COMPLETED ·Phase: NA
-
Integrated Disease Management of Heart Failure in Primary Care
NCT04066907 ·Status: UNKNOWN ·Phase: NA
-
Feasibility Assessment of the Aquadex FlexFlowTM Ultrafiltration System in Treating Non Hospitalized Heart Failure Patients in Dedicated Heart Failure Centers
NCT01654926 ·Status: COMPLETED
-
Strategies for Assessment of Fluid Overload in Acute Decompensated Heart Failure
NCT04901039 ·Status: TERMINATED
-
Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients.
NCT02149940 ·Status: COMPLETED ·Phase: NA
-
Treatment of Severe Heart Failure by Ultrafiltration
NCT00360958 ·Status: COMPLETED ·Phase: PHASE4
-
Early Care After Discharge of HF Patients
NCT01820780 ·Status: COMPLETED ·Phase: NA
-
Effect of Dietary Sodium Restriction in the Management of Patients With Heart Failure and Diastolic Dysfunction
NCT01896908 ·Status: COMPLETED ·Phase: NA
-
Patient-centred Home-based Management of Heart Failure
NCT03655496 ·Status: COMPLETED ·Phase: PHASE1
-
The Effects of a High Fat and Low Carbohydrate Diet on Clinical Status in Patients With Heart Failure
NCT02150798 ·Status: COMPLETED ·Phase: NA
-
Renal Denervation to Treat Heart Failure With Preserved Ejection Fraction
NCT05030987 ·Status: RECRUITING ·Phase: NA
-
DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
NCT04877652 ·Status: COMPLETED
-
Heart Failure Patients Registry
NCT04709263 ·Status: COMPLETED
-
Loop Diuretic Therapy in Acutely Decompensated Heart Failure
NCT02638142 ·Status: RECRUITING
-
Acute Congestive Heart Failure Urgent Care Evaluation
NCT02634762 ·Status: COMPLETED
-
Effect of Post Discharge Follow-up on Readmission Rates for Congestive Heart Failure Patients
NCT01529463 ·Status: COMPLETED
-
Biomarkers and Therapeutic Modelisation in Heart Failure
NCT01655134 ·Status: UNKNOWN ·Phase: NA
-
Chemoreflex Sensitivity in HFpEF
NCT06309537 ·Status: NOT_YET_RECRUITING
-
Multidisciplinary Approach for High-risk Patients Leading to Early Diagnosis of Canadians With Heart Failure
NCT05860608 ·Status: WITHDRAWN ·Phase: NA
-
Predicted Prognosis in Heart Failure
NCT04009798 ·Status: UNKNOWN